Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Supemtek

EU flag

European Commission grants two new marketing authorisations for UCB’s Bimzelx

The drug is now approved to treat psoriatic arthritis and axial spondyloarthritis

- PMLiVE

AstraZeneca/Sanofi’s RSV antibody backed by FDA advisory committee for infants

RSV is the leading cause of hospitalisation for infants aged under one year in the US

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

Novartis receives EC approval for Cosentyx in hidradenitis suppurativa

There are around 200,000 people in Europe living with moderate to severe stages of HS

- PMLiVE

Sanofi’s frexalimab shows promise in relapsing forms of MS

The neurological disease affects approximately 2.8 million people worldwide

- PMLiVE

Sanofi/Regeneron’s Dupixent shows promise in chronic obstructive pulmonary disease

Approximately 300,000 people in the US live with uncontrolled COPD with evidence of type 2 inflammation

- PMLiVE

Novavax announces positive phase 2 results for COVID-19/influenza vaccine candidates

A combination COVID-19/influenza vaccine is included in the mid-stage study

- PMLiVE

CureVac announces start of phase 1/2 seasonal influenza vaccine trial

The multivalent mRNA candidates have been developed in collaboration with GSK

- PMLiVE

Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

- PMLiVE

Sanofi signs agreement worth up to $750m for Maze’s Pompe disease drug

The candidate has recently cleared its first phase 1 clinical trial

- PMLiVE

WHO announces launch of new pandemic preparedness initiative

The guidance focuses on respiratory pathogens, including influenza and RSV

- PMLiVE

Janssen’s Akeega receives EC approval for metastatic prostate cancer

The authorisation marks the first worldwide approval of the niraparib-based combination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links